A5074855240- Heart Failure Treatment and Management
- Peptidase Inhibition and Analysis
- Advanced Proteomics Techniques and Applications
- Electrospun Nanofibers in Biomedical Applications
- Cardiovascular Function and Risk Factors
- Cardiac Structural Anomalies and Repair
- Cardiomyopathy and Myosin Studies
- Genomics and Rare Diseases
- Tissue Engineering and Regenerative Medicine
- Neurogenetic and Muscular Disorders Research
- Advanced Biosensing Techniques and Applications
- GDF15 and Related Biomarkers
- Muscle Physiology and Disorders
- Congenital heart defects research
- Apelin-related biomedical research
- Amyotrophic Lateral Sclerosis Research
Novartis (United States)
2023-2024
The National Institute of Health (NIH) Library integrated network-based cellular signatures (LINCS) program is premised on the generation a publicly available data resource cell-based biochemical responses or "signatures" to genetic environmental perturbations. NeuroLINCS uses human inducible pluripotent stem cells (hiPSCs), derived from patients and healthy controls, differentiated into motor neuron cell cultures. This multi-laboratory effort strives establish i) robust multi-omic workflows...
Prognostic markers and biological pathways linked to detrimental clinical outcomes in heart failure with preserved ejection fraction (HFpEF) remain incompletely defined.
To evaluate the prevalence of pathogenic variants in genes associated with dilated cardiomyopathy (DCM) a clinical trial population heart failure and reduced ejection fraction (HFrEF) describe baseline characteristics by variant carrier status.This was post hoc analysis Phase 3 PARADIGM-HF trial. Forty-four genes, divided into three tiers, based on definitive, moderate or limited evidence association DCM, were assessed for rare predicted loss-of-function (pLoF) variants, which prioritized...
Introduction: Prognostic markers and biological pathways linked to detrimental clinical outcomes in heart failure with preserved ejection fraction (HFpEF) remain incompletely defined. Goal: To identify serum proteins associated risk for HF hospitalization (HFH) cardiovascular (CV) death patients HFpEF, including differential associations HFpEF compared HFrEF. Methods: We measured levels of 4123 unique 1117 the PARAGON-HF trial using a modified aptamer proteomic assay. Baseline protein...
Abstract Background Systematically characterizing associations between circulating proteins and risk for subsequent clinical events may improve prediction shed light on unrecognized biological pathways in heart failure (HF). Large-scale assays measuring thousands of now enable broad proteomic investigation trials. Methods Serum levels 4076 were measured at baseline the ATMOSPHERE (n=1258, 487 over 6 years) PARADIGM-HF (n=1257, 287 4 trials chronic HF with reduced ejection fraction using a...